Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections

Bao Sun; Shiqiong Huang; Jiecan Zhou

doi:10.3389/fphar.2020.592439

Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections

Front Pharmacol. 2021 Jan 29:11:592439. doi: 10.3389/fphar.2020.592439. eCollection 2020.

Authors

Bao Sun^{1

2}, Shiqiong Huang³, Jiecan Zhou⁴

Affiliations

¹ Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
² Institute of Clinical Pharmacy, Central South University, Changsha, China.
³ Department of Pharmacy, The First Hospital of Changsha, Changsha, China.
⁴ Institute of Clinical Medicine, The First Affiliated Hospital, University of South China, Hengyang, China.

Abstract

Diabetes mellitus (DM) increases the risk of viral infections especially during the period of poor glycemic controls. Emerging evidence has reported that DM is one of the most common comorbidities in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection, also referred to as COVID-19. Moreover, the management and therapy are complex for individuals with diabetes who are acutely unwell with suspected or confirmed COVID-19. Here, we review the role of antidiabetic agents, mainly including insulin, metformin, pioglitazone, dipeptidyl peptidase-4 (DPP4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists in DM patients with coronavirus infection, addressing the clinical therapeutic choices for these subjects.

Keywords: COVID-19; antidiabetic agents; coronavirus infection; diabetes mellitus; therapeutic choices.

Publication types

Review